Clinical Trial Update: Fexofenadine as Adjuvant Therapy in Parkinson Disease [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating fexofenadine as adjuvant therapy for Parkinson disease is currently recruiting, sponsored by Tanta University.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Fexofenadine (fexofenadine)

Snippet

Sponsor: Tanta University | Conditions: Parkinson Disease | Phase 2, Phase 3 | Status: RECRUITING